DUSP4 promotes doxorubicin resistance in gastric cancer through epithelial-mesenchymal transition

Xing Kang; Minhuan Li; Hao Zhu; Xiaofeng Lu; Ji Miao; Shangce Du; Xuefeng Xia; Wenxian Guan

doi:10.18632/oncotarget.21522

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

DUSP4 promotes doxorubicin resistance in gastric cancer through epithelial-mesenchymal transition

Xing Kang, Minhuan Li, Hao Zhu, Xiaofeng Lu, Ji Miao, Shangce Du, Xuefeng Xia _ and Wenxian Guan

PDF | HTML | How to cite

Oncotarget. 2017; 8:94028-94039. https://doi.org/10.18632/oncotarget.21522

Metrics: PDF 2808 views | HTML 2890 views | ?

Abstract

Xing Kang1,*, Minhuan Li2,*, Hao Zhu3,*, Xiaofeng Lu1, Ji Miao1, Shangce Du1, Xuefeng Xia1 and Wenxian Guan1

1Department of General Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, Jiangsu Province, China

2Department of Laboratory Medicine, Sir Run Run Hospital, Nanjing Medical University, Nanjing, 210000, Jiangsu Province, China

3Department of Gastroenterology, The Afflicted Drum Tower Hospital, Nanjing University Medical School, Nanjing 210008, Jiangsu Province, China

*These authors have contributed equally to this work

Correspondence to:

Xuefeng Xia, email: [email protected]

Wenxian Guan, email: [email protected]

Keywords: chemoresistance, doxorubicin, DUSP4, epithelial-mesenchymal transition, gastric cancer

Received: August 08, 2017 Accepted: September 03, 2017 Published: October 04, 2017

ABSTRACT

Chemoresistance limits treatment efficacy in gastric cancer and doxorubicin resistance is common in gastric cancer cells. Dual specificity phosphatase 4 (DUSP4) has been associated with tumor progression. This study aimed to investigate the mechanism of DUSP4 regulating doxorubicin resistance in gastric cancer cells. Cell Counting Kit-8 (CCK-8) and 5-ethynyl-2′-deoxyuridine (EdU) incorporation assay were used to measure cell viability and proliferation in gastric cancer cells treated with doxorubicin. The expression of DUSP4, E-cadherin and Vimentin protein was detected by Western blotting. Overexpression of DUSP4 was more resistant to doxorubicin in gastric cancer cells. Knockdown of DUSP4 increased the sensitivity of gastric cancer cells to doxorubicin. Moreover, up-regulation of DUSP4 promoted the Epithelial-Mesenchymal Transition (EMT) in gastric cancer cells, but blocking the EMT using a Twist siRNA increased the sensitivity of gastric cancer cells to doxorubicin and confirmed the EMT was involved in DUSP4-mediated doxorubicin resistance. These findings demonstrated that DUSP4 could enhance doxorubicin resistance by promoting EMT in gastric cancer cells.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21522

Publication Alerts

Post-Publication Promotion

Research Papers:

DUSP4 promotes doxorubicin resistance in gastric cancer through epithelial-mesenchymal transition

Abstract